CD8A and endometrial cancer: Our study demonstrates that the proportion of CD20+ B lymphocytes and the CD8-to-CD20 lymphocytes ratio in the stroma of endometrial cancer serves as a predictive marker for response to immunotargeted therapy as well as a prognostic factor for progression-free survival in patients.